Table 4.
Comparison of hematologic toxicity and infectious complications by proportion of courses in patients who received CFAR (260 courses in 60 patients) versus historic high-risk patients (543 courses in 119 patients) who received FCR
| % of Courses |
||||
|---|---|---|---|---|
| CFAR (n = 260) |
High-risk FCR (n = 543) |
|||
| Grade 3 | Grade 4 | Grade 3 | Grade 4 | |
| Hematologic toxicity | ||||
| Neutropenia | 12 | 21 | 15 | 31 |
| Thrombocytopenia | 9 | 4 | 6 | 3 |
| Anemia | 3 | < 1 | 5 | < 1 |
| Infectious complications | ||||
| Major infection | 11 | 12 | ||
| Minor infection | 7 | 5 | ||
| Herpes simplex | < 1 | < 1 | ||
| Herpes zoster | < 1 | < 1 | ||
All patients in the CFAR study received pegfilgrastim on day 6 of each course of therapy whereas growth-factor support was not routine with FCR; major infection includes pneumonia, sepsis, septic shock, and fever of unknown origin requiring hospitalization; minor infection includes cellulitis, urinary tract infection, sinusitis, bronchitis, or upper respiratory tract infection.
FCR indicates fludarabine, cyclophosphamide, and rituximab; and CFAR, alemtuzumab added to FCR.